Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this ...

Obesity was tied with an increased risk of developing 16 health outcomes, a large longitudinal study showed. Risks correlated ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its tally of weight-loss candidates in clinical development to five.

Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Comcast Corp.

Roche has also made strategic acquisitions to expand its portfolio/pipeline. The recent collaboration with Zealand Pharma for its obesity candidate will expand its pipeline in the field of ...

Roche said CR-388 is ready to start phase 2 testing and will be developed for the treatment of obesity in people with and without type 2 diabetes. Like Zepbound and Novo Nordisk’s rival obesity ...

The European Union and Canada have led the charge against Trump's tariffs, threatening their own duties on tens of billions of dollars of American goods after the U.S. leveled blanket tariffs on steel ...

Are we truly on the brink of a cure for obesity? Or could neglecting the root causes risk worsening the very problems we seek ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

Potential US tariffs on pharmaceuticals could set off a ripple effect that extends far beyond the immediate price hikes, as ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...